Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

David Reardon, MD


Neuro-oncology

Make an Appointment
Watch Video

Physician

  • Clinical Director, Center for Neuro-Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Anti-angiogenic treatments
  • Brain and spinal tumors
  • Clinical trials in neuro-oncology
  • Convection-enhanced delivery
  • Immunotherapy
  • Targeted therapies

Diseases Treated

  • Brain Metastasis
  • Brain Tumors
  • Glioblastoma
  • Low-Grade Glioma
  • Lymphoma, Primary CNS
  • Meningioma

Contact Information

  • Appointments617-632-2166
  • Office Phone Number617-632-2166
  • Fax617-632-4773

Board Certification:

  • Neuro-Oncology
  • Pediatric Hematology/Oncology

Fellowship:

  • University of Michigan Hospital, MOTT Children's Hospital, Pediatric Hematology/Oncology

Residency:

  • Johns Hopkins Hospital, Pediatrics

Medical School:

  • Tufts Medical School

Research

The goals of my research are to: 1) identify exciting new treatments for brain cancer in the laboratory using animal models; 2) understand how these treatment approaches are working to fight cancer cells in order to optimize their effectiveness; and 3) move these promising approaches as quickly as possible to the clinic via clinical trials to help brain cancer patients. My laboratory focuses primarily on innovative and cutting-edge immunotherapies as single agents and in rationally designed, combinational approaches that include a wide array of additional therapies. We utilize a variety of brain tumor models that are grown intracranially and treatments that are applied systemically and/or locally. We have access to state-of-the-art imaging systems including MRI, PET scans and bioluminescence to help us evaluate the "success" of our treatments in our animal models. We collaborate with several outstanding cancer immunology scientists who can help us comprehensively evaluate mechanisms of action of our therapies by applying advanced techniques to evaluate harvested intracranial tumors, draining lymph nodes, other lymphatic organs and peripheral blood. Results of our work continue to drive new clinical trials evaluating promising approaches for brain cancer patients. My research effort also extends into the clinic and specifically includes designing and implementing clinical trials to effectively evaluate promising new therapies as quickly as possible for our patients.

The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro Oncol. 2021 08 02; 23(8):1261-1272.
View in: PubMed

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
View in: PubMed

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021 Jul; 9(7).
View in: PubMed

A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. Front Oncol. 2021; 11:679331.
View in: PubMed

Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
View in: PubMed

Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). Neuro Oncol. 2021 Apr 21.
View in: PubMed

Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. Acta Neurochir (Wien). 2021 07; 163(7):1883-1894.
View in: PubMed

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-ß and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab058.
View in: PubMed

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 2021 Apr 07; 11(1):7632.
View in: PubMed

The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. Neurosurg Clin N Am. 2021 Apr; 32(2):235-248.
View in: PubMed

IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 Jul; 34(7):1236-1244.
View in: PubMed

Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
View in: PubMed

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 May; 152(3):515-522.
View in: PubMed

Adolescent and young adult neuro-oncology: a comprehensive review. Neurooncol Pract. 2021 Jun; 8(3):236-246.
View in: PubMed

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
View in: PubMed

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci Rep. 2021 01 27; 11(1):2306.
View in: PubMed

Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021 May 15; 127(10):1620-1629.
View in: PubMed

Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol. 2020 12 01; 6(12):1972-1974.
View in: PubMed

Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply. JAMA Oncol. 2020 Dec 01; 6(12):1978-1979.
View in: PubMed

Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro Oncol. 2020 11 26; 22(11):1568-1579.
View in: PubMed

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287.
View in: PubMed

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
View in: PubMed

Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438.
View in: PubMed

Adult immuno-oncology: using past failures to inform the future. Neuro Oncol. 2020 09 29; 22(9):1249-1261.
View in: PubMed

Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis. Clin Transplant. 2020 11; 34(11):e14067.
View in: PubMed

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
View in: PubMed

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 07 01; 6(7):1003-1010.
View in: PubMed

PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? Clin Cancer Res. 2020 10 15; 26(20):5287-5296.
View in: PubMed

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
View in: PubMed

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
View in: PubMed

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. Sci Rep. 2020 05 29; 10(1):8766.
View in: PubMed

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020 12; 38(6):1784-1795.
View in: PubMed

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020 05 15; 22(5):601-612.
View in: PubMed

Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in: PubMed

Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Sci Rep. 2020 03 20; 10(1):5095.
View in: PubMed

Deep-Learning Detection of Cancer Metastases to the Brain on MRI. J Magn Reson Imaging. 2020 10; 52(4):1227-1236.
View in: PubMed

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
View in: PubMed

Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol. 2020 03 05; 22(3):369-380.
View in: PubMed

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 04 01; 26(7):1586-1594.
View in: PubMed

Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2020 Feb 01; 26(3):758.
View in: PubMed

An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning. Neurosurgery. 2020 02 01; 86(2):E184-E192.
View in: PubMed

Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. 2019 Oct 25; 1-11.
View in: PubMed

Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov; 80:101896.
View in: PubMed

Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
View in: PubMed

Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019 Sep; 22(9):1533.
View in: PubMed

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
View in: PubMed

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
View in: PubMed

Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. Theranostics. 2019; 9(21):6284-6299.
View in: PubMed

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
View in: PubMed

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 10 01; 25(19):5799-5807.
View in: PubMed

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 2019 08; 84(2):327-336.
View in: PubMed

Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019 Jun; 143(2):359-367.
View in: PubMed

Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019 05; 22(5):729-740.
View in: PubMed

Efficacy and safety of immune checkpoint blockade for brain metastases. CNS Oncol. 2019 06; 8(2):CNS33.
View in: PubMed

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486.
View in: PubMed

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in: PubMed

The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res. 2019 04 15; 25(8):2656-2663.
View in: PubMed

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 01 01; 21(1):26-36.
View in: PubMed

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 01 01; 21(1):106-114.
View in: PubMed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in: PubMed

Pseudoprogression: fact or wishful thinking in neuro-oncology? Lancet Oncol. 2018 12; 19(12):1561-1563.
View in: PubMed

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 12; 211(6):1342-1347.
View in: PubMed

Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2019 01 01; 25(1):290-299.
View in: PubMed

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418.
View in: PubMed

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
View in: PubMed

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730.
View in: PubMed

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
View in: PubMed

Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 08 02; 20(9):1262-1271.
View in: PubMed

Immunotherapy for glioblastoma: going viral. Nat Med. 2018 08; 24(8):1094-1096.
View in: PubMed

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. Eur J Cancer. 2018 09; 101:95-104.
View in: PubMed

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045.
View in: PubMed

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell. 2018 07 09; 34(1):163-177.e7.
View in: PubMed

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018 07 05; 20(8):1101-1112.
View in: PubMed

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
View in: PubMed

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 06 18; 20(7):897-906.
View in: PubMed

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018 05 18; 20(6):838-847.
View in: PubMed

Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. 2018 Oct; 14(24):2507-2520.
View in: PubMed

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686.
View in: PubMed

Concepts for Immunotherapies in Gliomas. Semin Neurol. 2018 02; 38(1):62-72.
View in: PubMed

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2574-2584.
View in: PubMed

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? J Neurooncol. 2018 May; 138(1):163-171.
View in: PubMed

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
View in: PubMed

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267.
View in: PubMed

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
View in: PubMed

Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep. 2018 01 09; 8(1):208.
View in: PubMed

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. J Neurooncol. 2018 Apr; 137(2):349-356.
View in: PubMed

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
View in: PubMed

High-grade Gliomas. Continuum (Minneap Minn). 2017 Dec; 23(6, Neuro-oncology):1548-1563.
View in: PubMed

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
View in: PubMed

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist. 2018 02; 23(2):157-e21.
View in: PubMed

Immunotherapy for glioblastoma: on the sidelines or in the game? Discov Med. 2017 11; 24(133):201-208.
View in: PubMed

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017 Dec; 80(6):1209-1217.
View in: PubMed

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
View in: PubMed

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017 Aug 01; 19(8):1119-1126.
View in: PubMed

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017 Nov; 14(11):695-707.
View in: PubMed

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):965-975.
View in: PubMed

Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369.
View in: PubMed

Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun; 13(6):363-374.
View in: PubMed

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017 06; 22(6):709-718.
View in: PubMed

Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515.
View in: PubMed

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635.
View in: PubMed

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in: PubMed

The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017 02; 39(2):225-239.
View in: PubMed

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65.
View in: PubMed

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology. 2017 Feb; 59(2):135-145.
View in: PubMed

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576.
View in: PubMed

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. J Mol Diagn. 2016 11; 18(6):864-871.
View in: PubMed

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
View in: PubMed

Adult brainstem gliomas. Cancer. 2016 09 15; 122(18):2799-809.
View in: PubMed

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in: PubMed

Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 09 01; 34(25):3107-8.
View in: PubMed

Checkpoint inhibition in meningiomas. Immunotherapy. 2016 06; 8(6):721-31.
View in: PubMed

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
View in: PubMed

Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-225.
View in: PubMed

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
View in: PubMed

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in: PubMed

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016 Mar 01; 34(7):731-9.
View in: PubMed

Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70.
View in: PubMed

Rare glial tumors. Handb Clin Neurol. 2016; 134:399-415.
View in: PubMed

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7.
View in: PubMed

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
View in: PubMed

Dedication: Andrew T. Parsa. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii2.
View in: PubMed

Introduction. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii1.
View in: PubMed

Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii32-vii40.
View in: PubMed

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol. 2015 Nov; 16(11):54.
View in: PubMed

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
View in: PubMed

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 2015 Oct 20; 6(32):34030-7.
View in: PubMed

Adult Atypical Teratoid/Rhabdoid Tumors. World Neurosurg. 2016 Jan; 85:197-204.
View in: PubMed

Glioblastoma in the elderly: making sense of the evidence. Neurooncol Pract. 2016 Jun; 3(2):77-86.
View in: PubMed

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in: PubMed

Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
View in: PubMed

Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep; 11(9):504-14.
View in: PubMed

Brachytherapy in the treatment of recurrent aggressive falcine meningiomas. J Neurooncol. 2015 Sep; 124(3):515-22.
View in: PubMed

Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 2015 Aug; 62 Suppl 1:198-9.
View in: PubMed

Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy. 2015; 7(6):603-6.
View in: PubMed

Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
View in: PubMed

One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
View in: PubMed

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. Oncologist. 2015 Jul; 20(7):727-8.
View in: PubMed

Multicentric Low-Grade Gliomas. World Neurosurg. 2015 Oct; 84(4):1045-50.
View in: PubMed

Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 2015 Aug; 17(8):1043-5.
View in: PubMed

A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):671-8.
View in: PubMed

Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
View in: PubMed

How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
View in: PubMed

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19; 519(7543):366-9.
View in: PubMed

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015 May; 17(5):708-17.
View in: PubMed

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
View in: PubMed

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in: PubMed

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):764-5.
View in: PubMed

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46.
View in: PubMed

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
View in: PubMed

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
View in: PubMed

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in: PubMed

Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in: PubMed

The future of antiangiogenic treatment in glioblastoma. Curr Opin Neurol. 2014 Dec; 27(6):675-82.
View in: PubMed

Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9.
View in: PubMed

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53.
View in: PubMed

Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
View in: PubMed

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
View in: PubMed

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13.
View in: PubMed

Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii24-35.
View in: PubMed

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
View in: PubMed

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in: PubMed

Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007.
View in: PubMed

Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
View in: PubMed

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015 Mar; 17(3):430-9.
View in: PubMed

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep; 15(10):1100-8.
View in: PubMed

A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. J Neurosurg. 2014 Sep; 121(3):536-42.
View in: PubMed

Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
View in: PubMed

Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
View in: PubMed

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
View in: PubMed

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
View in: PubMed

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
View in: PubMed

Update on the use of angiogenesis inhibitors in adult patients with brain tumors. Clin Adv Hematol Oncol. 2014 May; 12(5):293-303.
View in: PubMed

Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4.
View in: PubMed

Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging. 2014; 9:357-67.
View in: PubMed

Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. J Radiosurg SBRT. 2014; 3(1):37-42.
View in: PubMed

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May; 16(5):696-706.
View in: PubMed

Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210.
View in: PubMed

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in: PubMed

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
View in: PubMed

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol. 2013 Jun 20; 31(18_suppl):LBA2009.
View in: PubMed

Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
View in: PubMed

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in: PubMed

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol. 2013 Aug; 114(1):135-40.
View in: PubMed

Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
View in: PubMed

Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
View in: PubMed

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013; 18(3):273-80.
View in: PubMed

PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7.
View in: PubMed

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8.
View in: PubMed

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013 Apr; 2(2):185-95.
View in: PubMed

Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013.
View in: PubMed

Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol. 2013 Jan; 111(2):97-102.
View in: PubMed

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012 Oct 23; 107(9):1481-7.
View in: PubMed

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012 Nov; 110(2):245-50.
View in: PubMed

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61.
View in: PubMed

Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
View in: PubMed

Treatment of elderly patients with glioblastoma. Lancet Oncol. 2012 Jul; 13(7):656-7.
View in: PubMed

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
View in: PubMed

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1):63-70.
View in: PubMed

A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35.
View in: PubMed

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71.
View in: PubMed

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol. 2012 Jul; 108(3):499-506.
View in: PubMed

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18.
View in: PubMed

A pilot study of IL-2Ra blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One. 2012; 7(2):e31046.
View in: PubMed

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 01; 118(19):4759-67.
View in: PubMed

Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011 Dec; 2(12):1159-65.
View in: PubMed

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
View in: PubMed

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012 Mar; 107(1):213-21.
View in: PubMed

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol. 2012 Mar; 107(1):155-64.
View in: PubMed

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7.
View in: PubMed

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
View in: PubMed

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011 Oct 01; 29(28):e739-42.
View in: PubMed

Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011 Sep; 69(3):668-76.
View in: PubMed

Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert Opin Pharmacother. 2011 Oct; 12(14):2265-9.
View in: PubMed

Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012 Mar 01; 118(5):1302-12.
View in: PubMed

It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
View in: PubMed

Monoclonal antibody blockade of IL-2 receptor a during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011 Sep 15; 118(11):3003-12.
View in: PubMed

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011 Dec; 105(3):621-7.
View in: PubMed

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol. 2011 Dec; 105(3):601-6.
View in: PubMed

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. 2011 Jul 20; 29(21):2918-23.
View in: PubMed

Advances in malignant glioma drug discovery. Expert Opin Drug Discov. 2011 Jul; 6(7):739-53.
View in: PubMed

A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). J Clin Oncol. 2011 May 20; 29(15_suppl):2070.
View in: PubMed

Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J Clin Oncol. 2011 May 20; 29(15_suppl):2030.
View in: PubMed

Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2056.
View in: PubMed

Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2055.
View in: PubMed

Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. J Clin Oncol. 2011 May 20; 29(15_suppl):9090.
View in: PubMed

Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2082.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
View in: PubMed

Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2098.
View in: PubMed

Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039.
View in: PubMed

A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2010.
View in: PubMed

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011 Dec 01; 117(23):5351-8.
View in: PubMed

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011 Jun 15; 17(12):4119-24.
View in: PubMed

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):2018-24.
View in: PubMed

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93.
View in: PubMed

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011 Apr; 9(4):414-27.
View in: PubMed

Knee deep in the nerve. Surv Ophthalmol. 2011 Jul-Aug; 56(4):362-70.
View in: PubMed

Cilengitide: an RGD pentapeptide a?ß3 and a?ß5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011 Mar; 7(3):339-54.
View in: PubMed

Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.
View in: PubMed

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46.
View in: PubMed

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep. 2011 Feb; 13(1):42-9.
View in: PubMed

A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One. 2011 Jan 26; 6(1):e16031.
View in: PubMed

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.
View in: PubMed

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):58-66.
View in: PubMed

Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. Br J Radiol. 2011 Apr; 84(1000):327-33.
View in: PubMed

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9.
View in: PubMed

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011 Jun; 103(2):371-9.
View in: PubMed

Treatment recommendations for primary extradural meningiomas. Cancer. 2011 Jan 01; 117(1):24-38.
View in: PubMed

Targeting integrins in malignant glioma. Target Oncol. 2010 Sep; 5(3):175-81.
View in: PubMed

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec; 12(12):1300-10.
View in: PubMed

Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010 Aug; 113(2):301-9.
View in: PubMed

Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol. 2010 Sep; 11(9):809-11.
View in: PubMed

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010 Oct; 12(10):1061-70.
View in: PubMed

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77.
View in: PubMed

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol. 2011 Jan; 101(1):155-9.
View in: PubMed

Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. Oncologist. 2010; 15(6):636-47.
View in: PubMed

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol. 2011 Jan; 101(1):57-66.
View in: PubMed

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.
View in: PubMed

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr; 11(4):373-82.
View in: PubMed

Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer. 2010 Feb 01; 116(3):695-704.
View in: PubMed

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009 Dec 15; 101(12):1986-94.
View in: PubMed

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009 Dec 15; 101(12):1995-2004.
View in: PubMed

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9.
View in: PubMed

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 01; 115(15):3501-11.
View in: PubMed

Current available therapies and future directions in the treatment of malignant gliomas. Biologics. 2009; 3:15-25.
View in: PubMed

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009 Jul 01; 115(13):2964-70.
View in: PubMed

Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med. 2009 Jul; 15(7):726; author reply 727.
View in: PubMed

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010 Jan; 96(2):219-30.
View in: PubMed

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol. 2009 Dec; 95(3):393-400.
View in: PubMed

Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):e13016.
View in: PubMed

Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2015.
View in: PubMed

Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2034.
View in: PubMed

Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):e13025.
View in: PubMed

Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2045.
View in: PubMed

A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13024.
View in: PubMed

Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13007.
View in: PubMed

Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2040.
View in: PubMed

Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13002.
View in: PubMed

Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol. 2009 May 20; 27(15_suppl):2046.
View in: PubMed

Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol. 2009 May 20; 27(15_suppl):e13004.
View in: PubMed

Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2021.
View in: PubMed

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009 May 15; 115(10):2188-98.
View in: PubMed

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009 Oct; 95(1):129-134.
View in: PubMed

Cancer: The nuances of therapy. Nature. 2009 Mar 19; 458(7236):290-2.
View in: PubMed

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct; 11(5):556-61.
View in: PubMed

Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009 Mar; 18(3):277-92.
View in: PubMed

IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8):765-73.
View in: PubMed

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009 Aug; 94(1):79-85.
View in: PubMed

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10; 27(8):1262-7.
View in: PubMed

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 01; 15(3):1064-8.
View in: PubMed

Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage. 2009 Aug; 47 Suppl 2:T143-51.
View in: PubMed

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7.
View in: PubMed

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 01; 14(21):7068-73.
View in: PubMed

Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009 Feb; 11(1):80-91.
View in: PubMed

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct; 10(5):745-51.
View in: PubMed

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008 Aug; 17(8):1225-35.
View in: PubMed

Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051.
View in: PubMed

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2074.
View in: PubMed

Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2084.
View in: PubMed

Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2042.
View in: PubMed

Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea. J Clin Oncol. 2008 May 20; 26(15_suppl):2071.
View in: PubMed

Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2011.
View in: PubMed

Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):13008.
View in: PubMed

Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. J Clin Oncol. 2008 May 20; 26(15_suppl):2026.
View in: PubMed

Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). J Clin Oncol. 2008 May 20; 26(15_suppl):2057.
View in: PubMed

Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol. 2008 May 20; 26(15_suppl):2021.
View in: PubMed

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May; 8(5):717-32.
View in: PubMed

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun; 10(3):320-9.
View in: PubMed

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
View in: PubMed

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun; 10(3):330-40.
View in: PubMed

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr; 10(2):182-9.
View in: PubMed

The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb; 9(1):1-22.
View in: PubMed

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan; 49(1):30-8.
View in: PubMed

Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol. 2008 Feb; 10(1):93-7.
View in: PubMed

Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov; 25(4):1111-39, x.
View in: PubMed

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20; 25(30):4722-9.
View in: PubMed

Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 01; 110(1):13-24.
View in: PubMed

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct; 34(7):779-85.
View in: PubMed

Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007 May; 7(5):675-87.
View in: PubMed

A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage. 2007; 37 Suppl 1:S116-9.
View in: PubMed

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 2007 Jul; 9(3):343-53.
View in: PubMed

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May; 34(4):405-13.
View in: PubMed

Neurofibromatosis type 2. Neurology. 2007 Mar 27; 68(13):E14.
View in: PubMed

Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr; 9(2):161-8.
View in: PubMed

Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. Psychooncology. 2007 Mar; 16(3):232-40.
View in: PubMed

Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol. 2007 Mar; 188(3):703-9.
View in: PubMed

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15; 13(4):1253-9.
View in: PubMed

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May; 83(1):53-60.
View in: PubMed

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):70-4.
View in: PubMed

3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006 Nov-Dec; 8(6):340-7.
View in: PubMed

Exercise interest and preferences among patients diagnosed with primary brain cancer. Support Care Cancer. 2007 Jan; 15(1):47-55.
View in: PubMed

An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1560.
View in: PubMed

Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11522.
View in: PubMed

Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1573.
View in: PubMed

A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1580.
View in: PubMed

Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1568.
View in: PubMed

Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1506.
View in: PubMed

Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11504.
View in: PubMed

Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1539.
View in: PubMed

Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2529.
View in: PubMed

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun; 47(6):912-8.
View in: PubMed

Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer. 2006 May 15; 106(10):2224-32.
View in: PubMed

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1970-82.
View in: PubMed

Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006 Apr; 77(2):207-12.
View in: PubMed

Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1253-65.
View in: PubMed

Glioblastoma--more questions than answers? Nat Clin Pract Oncol. 2006 Feb; 3(2):60-1.
View in: PubMed

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64.
View in: PubMed

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):860-8.
View in: PubMed

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 01; 24(1):115-22.
View in: PubMed

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20; 23(36):9359-68.
View in: PubMed

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005 Nov 15; 11(22):8145-57.
View in: PubMed

Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005 Oct 15; 104(8):1693-9.
View in: PubMed

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 01; 104(7):1478-86.
View in: PubMed

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87.
View in: PubMed

Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005 Sep 01; 10:2645-68.
View in: PubMed

A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1565.
View in: PubMed

Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. J Clin Oncol. 2005 Jun; 23(16_suppl):1515.
View in: PubMed

Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):1510.
View in: PubMed

A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. J Clin Oncol. 2005 Jun; 23(16_suppl):3063.
View in: PubMed

A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1540.
View in: PubMed

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005 Jun; 46(6):1042-51.
View in: PubMed

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15; 103(2):329-38.
View in: PubMed

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol. 2005 Jan; 7(1):90-6.
View in: PubMed

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. . 2005 Jan; 4(1):101-12.
View in: PubMed

Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther. 2004 Sep; 4(9):1453-71.
View in: PubMed

Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1569.
View in: PubMed

Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1554.
View in: PubMed

A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1512.
View in: PubMed

A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9682.
View in: PubMed

A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1513.
View in: PubMed

Kluver-Bucy syndrome related to glioma. Neurology. 2004 Jul 13; 63(1):184.
View in: PubMed

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr; 6(2):145-53.
View in: PubMed

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr; 6(2):134-44.
View in: PubMed

Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 01; 22(1):133-42.
View in: PubMed

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct; 65(1):27-35.
View in: PubMed

High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 01; 21(11):2187-91.
View in: PubMed

Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):9-14.
View in: PubMed

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003 Apr 15; 97(8):1963-8.
View in: PubMed

Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15; 21(4):646-51.
View in: PubMed

Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 01; 20(13):2951-8.
View in: PubMed

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
View in: PubMed

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 01; 20(5):1389-97.
View in: PubMed

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer. 2001 Jun 15; 84(12):1591-8.
View in: PubMed

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001 Mar 15; 20(11):1388-97.
View in: PubMed

Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant. 2001; 7(5):284-93.
View in: PubMed

Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90.
View in: PubMed

Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):247-51.
View in: PubMed

Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg. 2000 Apr; 32(4):187-91.
View in: PubMed

Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999 Dec; 17(12):3720-8.
View in: PubMed

Malignant evolution of choroid plexus papilloma. Pediatr Neurosurg. 1999 Sep; 31(3):127-30.
View in: PubMed

Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol. 1999 Jun; 17(6):1825-8.
View in: PubMed

Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):249-54.
View in: PubMed

Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999 Mar; 24(3):230-7.
View in: PubMed

High-grade pediatric spinal cord tumors. Pediatr Neurosurg. 1999 Jan; 30(1):1-5.
View in: PubMed

Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg. 1998 Jul; 29(1):29-35.
View in: PubMed

Chromosomal localization of the human smoothened gene (SMOH) to 7q32. 3 by fluorescence in situ hybridization and radiation hybrid mapping. Genomics. 1998 May 15; 50(1):112-4.
View in: PubMed

MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar; 16(3):897-906.
View in: PubMed

Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997 Sep 15; 57(18):4042-7.
View in: PubMed

Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 1994 Mar 01; 73(5):1526-32.
View in: PubMed

The microfocus assay system (mfas) - a simple quantitative assay to identify inhibitory drugs targeted against specific oncogenes. Oncol Rep. 1994 Jan; 1(1):37-41.
View in: PubMed

Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood. 1992 Jul 15; 80(2):551-5.
View in: PubMed

Differential impact of abortion on adolescents and adults. Adolescence. 1992; 27(105):161-72.
View in: PubMed

Virus-associated hemophagocytic syndrome following bone marrow transplantation. Am J Pediatr Hematol Oncol. 1991; 13(3):305-9.
View in: PubMed

The size and number of bone marrow megakaryocytes in malignant lymphoma and their relationship to abnormalities in platelet count. Am J Hematol. 1990 Dec; 35(4):225-31.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top